UNITED THERAPEUTICS CORPORATION

NASDAQ: UTHR (United Therapeutics Corporation)

Last update: 26 Oct, 4:06AM

418.58

-7.63 (-1.79%)

  • 1D -1.79%
  • 5D -6.03%
  • 1M -4.87%
  • 6M 34.68%
  • YTD 16.20%
  • 1Y 4.53%
  • 5Y 200.53%
Previous Close 426.21
Open 426.40
Volume 375,453
Avg. Volume (3M) 812,004
Market Cap 18,930,808,832
Price / Earnings (TTM) 16.34
Price / Earnings (Forward) 15.29
Price / Sales 6.98
Price / Book 2.80
52 Weeks Range
266.98 (-36%) — 459.48 (9%)
Earnings Date 29 Oct 2025
Profit Margin 40.44%
Operating Margin (TTM) 48.19%
Diluted EPS (TTM) 25.11
Quarterly Revenue Growth (YOY) 17.20%
Quarterly Earnings Growth (YOY) 5.10%
Total Debt/Equity (MRQ) 2.94%
Current Ratio (MRQ) 5.46
Operating Cash Flow (TTM) 1.41 B
Levered Free Cash Flow (TTM) 825.79 M
Return on Assets (TTM) 12.93%
Return on Equity (TTM) 19.94%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bullish Mixed
Drug Manufacturers - Specialty & Generic (Global) Bullish Mixed
Stock United Therapeutics Corporation Bullish Bullish

AIStockmoo Score

0.7
Analyst Consensus 3.0
Insider Activity -3.5
Price Volatility -0.5
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 0.70

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
UTHR 19 B - 16.34 2.80
VTRS 12 B 4.64% - 0.760
HCM 3 B - 5.54 2.25
NBIX 15 B - 36.37 5.03
LNTH 4 B - 14.49 3.07
KNSA 3 B - 85.27 5.61

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Mid Value
% Held by Insiders 1.75%
% Held by Institutions 100.69%
52 Weeks Range
266.98 (-36%) — 459.48 (9%)
Price Target Range
423.00 (1%) — 600.00 (43%)
High 600.00 (UBS, 43.34%) Buy
Median 525.00 (25.42%)
Low 423.00 (Wells Fargo, 1.06%) Hold
Average 521.89 (24.68%)
Total 6 Buy, 3 Hold
Avg. Price @ Call 429.03
Firm Date Target Price Call Price @ Call
UBS 06 Nov 2025 600.00 (43.34%) Buy 454.00
29 Sep 2025 580.00 (38.56%) Buy 424.31
HC Wainwright & Co. 30 Oct 2025 525.00 (25.42%) Buy 453.53
05 Sep 2025 500.00 (19.45%) Buy 400.52
RBC Capital 30 Oct 2025 587.00 (40.24%) Buy 453.53
26 Sep 2025 569.00 (35.94%) Buy 432.66
Wells Fargo 30 Oct 2025 423.00 (1.06%) Hold 453.53
03 Sep 2025 414.00 (-1.09%) Hold 391.45
Morgan Stanley 10 Oct 2025 435.00 (3.92%) Hold 440.00
Cantor Fitzgerald 10 Sep 2025 525.00 (25.42%) Buy 396.50
Oppenheimer 05 Sep 2025 575.00 (37.37%) Buy 400.52
B of A Securities 02 Sep 2025 463.00 (10.61%) Hold 404.81
Jefferies 02 Sep 2025 564.00 (34.74%) Buy 404.81
Show more
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BENKOWITZ MICHAEL - 429.85 -45,000 -19,343,250
CAUSEY CHRISTOPHER - 438.66 -450 -197,397
EDGEMOND JAMES - 437.33 -21,000 -9,183,930
MAHON PAUL A - 453.53 -11,000 -4,988,830
ROTHBLATT MARTINE A - 441.70 -40,000 -17,668,040
Aggregate Net Quantity -117,450
Aggregate Net Value ($) -51,381,447
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 440.42
Name Holder Date Type Quantity Price Value ($)
ROTHBLATT MARTINE A Officer 07 Nov 2025 Automatic sell (-) 4,000 448.91 1,795,640
ROTHBLATT MARTINE A Officer 07 Nov 2025 Option execute 4,000 - -
ROTHBLATT MARTINE A Officer 06 Nov 2025 Automatic sell (-) 4,000 454.00 1,816,000
ROTHBLATT MARTINE A Officer 06 Nov 2025 Option execute 4,000 - -
ROTHBLATT MARTINE A Officer 05 Nov 2025 Automatic sell (-) 4,000 447.45 1,789,800
ROTHBLATT MARTINE A Officer 05 Nov 2025 Option execute 4,000 - -
EDGEMOND JAMES Officer 04 Nov 2025 Automatic sell (-) 21,000 437.33 9,183,930
EDGEMOND JAMES Officer 04 Nov 2025 Option execute 21,000 - -
ROTHBLATT MARTINE A Officer 04 Nov 2025 Automatic sell (-) 4,000 437.33 1,749,320
ROTHBLATT MARTINE A Officer 04 Nov 2025 Option execute 4,000 - -
CAUSEY CHRISTOPHER Director 03 Nov 2025 Disposed (-) 450 438.66 197,397
BENKOWITZ MICHAEL Officer 03 Nov 2025 Automatic sell (-) 22,500 438.66 9,869,850
BENKOWITZ MICHAEL Officer 03 Nov 2025 Option execute 22,500 - -
ROTHBLATT MARTINE A Officer 03 Nov 2025 Automatic sell (-) 4,000 438.66 1,754,640
ROTHBLATT MARTINE A Officer 03 Nov 2025 Option execute 4,000 - -
ROTHBLATT MARTINE A Officer 31 Oct 2025 Automatic sell (-) 4,000 445.43 1,781,720
ROTHBLATT MARTINE A Officer 31 Oct 2025 Option execute 4,000 - -
MAHON PAUL A Officer 30 Oct 2025 Automatic sell (-) 11,000 453.53 4,988,830
MAHON PAUL A Officer 30 Oct 2025 Option execute 11,000 - -
ROTHBLATT MARTINE A Officer 30 Oct 2025 Automatic sell (-) 4,000 453.53 1,814,120
ROTHBLATT MARTINE A Officer 30 Oct 2025 Option execute 4,000 - -
ROTHBLATT MARTINE A Officer 29 Oct 2025 Automatic sell (-) 4,000 455.32 1,821,280
ROTHBLATT MARTINE A Officer 29 Oct 2025 Option execute 4,000 - -
ROTHBLATT MARTINE A Officer 28 Oct 2025 Automatic sell (-) 4,000 415.34 1,661,360
ROTHBLATT MARTINE A Officer 28 Oct 2025 Option execute 4,000 - -
BENKOWITZ MICHAEL Officer 27 Oct 2025 Automatic sell (-) 22,500 421.04 9,473,400
BENKOWITZ MICHAEL Officer 27 Oct 2025 Option execute 22,500 - -
ROTHBLATT MARTINE A Officer 27 Oct 2025 Automatic sell (-) 4,000 421.04 1,684,160
ROTHBLATT MARTINE A Officer 27 Oct 2025 Option execute 4,000 - -
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria